Search

Your search keyword '"Felbamate"' showing total 34 results
Start Over Descriptor "Felbamate" Publication Type News
34 results on '"Felbamate"'

2. Patent Issued for Dry powder inhaler and system for drug delivery (USPTO 11998683)

Subjects
Mannkind Corp. -- Intellectual property, Drugs -- Vehicles, Patient compliance, Felbamate, Lamotrigine -- Intellectual property, Drug delivery systems -- Intellectual property, Pharmaceutical industry -- Intellectual property, Health
Abstract

2024 JUN 24 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- MannKind Corporation (Danbury, Connecticut, United States) has been issued patent number 11998683, according to news [...]

Published
2024

3. Quotation For The Supply Of Felbamate Oral Suspension

Subjects
Felbamate, Oral medication, Business, international
Abstract

Tenders are invited for quotation for the supply of felbamate oral suspension Felbamate oral suspension Procurement type:supplies Cft involves: a public contract End of clarification period: 27/04/2024 12:00 Time-limit for [...]

Published
2024

4. Call For Quotations For The Supply Of Felbamate Oral Suspension

Subjects
Felbamate, Oral medication, Business, international
Abstract

Tenders are invited for call for quotations for the supply of felbamate oral suspension Felbamate oral suspension Procurement type:supplies Cft involves: a public contract End of clarification period: 08/04/2024 12:00 [...]

Published
2024

6. Patent Issued for Cardiopathy-reducing phosphodiester lipids (USPTO 11746119)

Subjects
Heart diseases, Halofantrine -- Intellectual property, Mirabegron, Trimipramine -- Intellectual property, Sibutramine -- Intellectual property, Tizanidine -- Intellectual property, Amoxapine -- Intellectual property, Posaconazole, Felbamate, Perflutren -- Intellectual property, Terbutaline -- Intellectual property, Antimitotic agents -- Intellectual property, Thioridazine -- Intellectual property, Fosphenytoin -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Sparfloxacin -- Intellectual property, Lipids, Pentamidine isethionate -- Intellectual property, Nilotinib, Antineoplastic agents -- Intellectual property, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Hydrochlorothiazide -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract

2023 OCT 1 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by [...]

Published
2023

7. Patent Issued for Cardiopathy-reducing phosphodiester lipids (USPTO 11643424)

Subjects
Heart diseases, Halofantrine -- Intellectual property, Mirabegron, Trimipramine -- Intellectual property, Sibutramine -- Intellectual property, Tizanidine -- Intellectual property, Amoxapine -- Intellectual property, Posaconazole, Felbamate, Perflutren -- Intellectual property, Antimitotic agents -- Intellectual property, Terbutaline -- Intellectual property, Thioridazine -- Intellectual property, Fosphenytoin -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Sparfloxacin -- Intellectual property, Lipids, Pentamidine isethionate -- Intellectual property, Antineoplastic agents -- Intellectual property, Nilotinib, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Hydrochlorothiazide -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract

2023 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- A patent by the inventors Augustine, John Kallikat (Bangalore, IN), Bouchard, Annie (Stoke, CA), [...]

Published
2023

8. Patent Application Titled 'Novel Lipids' Published Online (USPTO 20220056057)

Subjects
Heart diseases, Halofantrine -- Intellectual property, Sibutramine -- Intellectual property, Trimipramine -- Intellectual property, Mirabegron, Tizanidine -- Intellectual property, Amoxapine -- Intellectual property, Povidone -- Intellectual property, Posaconazole, Felbamate, Perflutren -- Intellectual property, Terbutaline -- Intellectual property, Antimitotic agents -- Intellectual property, Thioridazine -- Intellectual property, Fosphenytoin -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Sparfloxacin -- Intellectual property, Lipids, Pentamidine isethionate -- Intellectual property, Nilotinib, Antineoplastic agents -- Intellectual property, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Hydrochlorothiazide -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract

2022 MAR 20 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2022

9. Patent Issued for Dry powder inhaler and system for drug delivery (USPTO 11241549)

Subjects
Mannkind Corp. -- Intellectual property, Drugs -- Vehicles, Patient compliance, Argatroban -- Intellectual property, Felbamate, Lamotrigine -- Intellectual property, Drug delivery systems -- Intellectual property, Pharmaceutical industry -- Intellectual property, Health
Abstract

2022 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- MannKind Corporation (Westlake Village, California, United States) has been issued patent number 11241549, [...]

Published
2022

10. Felbamate 600 Mg Comp

Subjects
Merck & Company Inc., Felbamate, Pharmaceutical industry, Business, international
Abstract

Contract awarded for Felbamate 600 mg comp Date of conclusion of the contract: 03-09-2020 Contract price: 2. 438,21 Deadline: 120 days Place of execution - Country, District, Municipality: Portugal Contractor [...]

Published
2020

11. Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome

Subjects
Felbamate, Patient compliance, Seizures (Medicine) -- Care and treatment, Rufinamide, Cholesterol, Nervous system diseases, Enzymes, Diseases, Business, international, Law
Abstract

(GlobeNewswire) - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced initial data from its [...]

Published
2020

13. Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO

Subjects
Felbamate, Epilepsy, Neurodegenerative diseases, Status epilepticus, Central nervous system, Diseases, Company securities, Company business planning, General interest, News, opinion and commentary
Abstract

SUWON: Bio-Pharm Solutions has issued the following news release: Bio-Pharm Solutions Co., Ltd. has expanded its clinical pipelines from infantile spasms (IS) to status epilepticus (SE) and Alzheimer's disease. Based [...]

Published
2020

14. Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO

Subjects
Yukong Ltd. -- Planning -- Securities, Petroleum industry -- Planning -- Securities, Felbamate, Epilepsy, Neurodegenerative diseases, Drugs, Status epilepticus, Central nervous system, Diseases, Company securities, Company business planning, Business, international, Law
Abstract

Bio-Pharm Solutions Co., Ltd. has expanded its clinical pipelines from infantile spasms (IS) to status epilepticus (SE) and Alzheimer's disease. Based on the performance of its first pipeline, an infantile [...]

Published
2020

15. Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO

Subjects
Yukong Ltd. -- Securities, Petroleum industry -- Securities, Felbamate, Epilepsy, Company securities, Business, News, opinion and commentary
Abstract

The oral medication for Infantile spasms (IS) is in phase 2 clinical trials in Korea and the US, and the IV medication for Status epilepticus (SE) is in phase 1 [...]

Published
2020

16. Global epilepsy drug market is expected to grow with a CAGR of 7.1% over the forecast period from 2019-2025

Subjects
Anticonvulsants -- Reports, Epilepsy -- Reports, Pharmaceutical industry -- Forecasts and trends -- Reports, Oxcarbazepine, Medium term notes, Motor vehicle drivers, Felbamate, Eslicarbazepine acetate, Lamotrigine, Lacosamide, Market trend/market analysis, General interest, News, opinion and commentary
Abstract

FRANCE: ReportLinker FR has issued the following press release: Reportlinker.com announces the release of the report 'Epilepsy Drug Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025' [...]

Published
2020

17. Global epilepsy drug market is expected to grow with a CAGR of 7.1% over the forecast period from 2019-2025

Subjects
Anticonvulsants -- Reports, Epilepsy -- Reports, Pharmaceutical industry -- Forecasts and trends -- Reports, Oxcarbazepine, Medium term notes, Motor vehicle drivers, Felbamate, Eslicarbazepine acetate, Lamotrigine, Lacosamide, Market trend/market analysis, Banking, finance and accounting industries, Business
Abstract

New York, Jan 20, 2020 (GLOBE NEWSWIRE via COMTEX) -- Reportlinker.com announces the release of the report 'Epilepsy Drug Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to [...]

Published
2020

18. Patent Application Titled 'Novel Lipids' Published Online (USPTO 20210198294)

Subjects
Heart diseases, Halofantrine -- Intellectual property, Sibutramine -- Intellectual property, Trimipramine -- Intellectual property, Mirabegron, Tizanidine -- Intellectual property, Amoxapine -- Intellectual property, Povidone -- Intellectual property, Posaconazole, Felbamate, Perflutren -- Intellectual property, Terbutaline -- Intellectual property, Antimitotic agents -- Intellectual property, Thioridazine -- Intellectual property, Fosphenytoin -- Intellectual property, Fingolimod -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Sparfloxacin -- Intellectual property, Lipids, Pentamidine isethionate -- Intellectual property, Nilotinib, Antineoplastic agents -- Intellectual property, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Hydrochlorothiazide -- Intellectual property, Biotechnology industry, Pharmaceuticals and cosmetics industries, Health
Abstract

2021 JUL 25 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application [...]

Published
2021

19. Researchers Submit Patent Application, 'Prevention Of The Risks Associated With Drug-Induced Qt Interval Prolongation By Using A Specific Inhibitor Of The Production Of Ros Of Miochondrial Origin', for Approval (USPTO 20210052549)

Subjects
Halofantrine -- Intellectual property, Trimipramine -- Intellectual property, Mirabegron, Tizanidine -- Intellectual property, Posaconazole, Cardiovascular diseases -- Prevention, Felbamate, Antimitotic agents -- Intellectual property, Thioridazine -- Intellectual property, Fingolimod -- Intellectual property, Efavirenz -- Intellectual property, Tazobactam -- Intellectual property, Anti-arrhythmia drugs -- Intellectual property, Antipsychotic drugs, Pantoprazole -- Intellectual property, Trifluridine -- Intellectual property, Sparfloxacin -- Intellectual property, BCR-ABL tyrosine kinase inhibitors, Pentamidine isethionate -- Intellectual property, Antineoplastic agents -- Intellectual property, Moexipril -- Intellectual property, Indapamide -- Intellectual property, Rilpivirine -- Intellectual property, Ezogabine, Alfuzosin -- Intellectual property, Dolasetron -- Intellectual property, Droperidol, Nervous system diseases -- Prevention, Metronidazole -- Intellectual property, Dexmedetomidine -- Intellectual property, Atazanavir -- Intellectual property, Ivabradine, Palonosetron -- Intellectual property, Hydrochlorothiazide -- Intellectual property, Business, Health
Abstract

2021 MAR 19 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Patent Business Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors [...]

Published
2021

20. Global Epilepsy Drug Market Analysis, Trends, Market Size, and Forecasts, 2017-2019 & 2019-2025

Subjects
Anticonvulsants -- Reports -- Market size, Epilepsy -- Reports, Pharmaceutical industry -- Industry forecasts -- Reports -- Market size, Oxcarbazepine, Medium term notes, Felbamate, Lamotrigine, Lacosamide, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following press release: The 'Epilepsy Drug Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025' report has been added to [...]

Published
2019

21. Global Epilepsy Drug Market Analysis, Trends, Market Size, and Forecasts, 2017-2019 & 2019-2025

Subjects
Anticonvulsants -- Reports -- Market size, Epilepsy -- Reports, Pharmaceutical industry -- Industry forecasts -- Reports -- Market size, Oxcarbazepine, Medium term notes, Felbamate, Lamotrigine, Lacosamide, Business, Business, international
Abstract

M2 PRESSWIRE-July 17, 2019-: Global Epilepsy Drug Market Analysis, Trends, Market Size, and Forecasts, 2017-2019 & 2019-2025 (C)1994-2019 M2 COMMUNICATIONS RDATE:17072019 The 'Epilepsy Drug Market: Global Industry Analysis, Trends, Market [...]

Published
2019

22. Global Epilepsy Drug Market Analysis, Trends, Market Size, and Forecasts, 2017-2019 & 2019-2025 - ResearchAndMarkets.com

Subjects
Anticonvulsants -- Reports -- Market size, Epilepsy -- Reports, Pharmaceutical industry -- Industry forecasts -- Reports -- Market size, Oxcarbazepine, Medium term notes, Felbamate, Lamotrigine, Lacosamide, Business, Business, international
Abstract

DUBLIN -- The 'Epilepsy Drug Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025' report has been added to ResearchAndMarkets.com's offering. The report predicts the global epilepsy [...]

Published
2019

23. Researchers Submit Patent Application, 'Use Of Cannabinoids In The Treatment Of Epilepsy', for Approval (USPTO 20200138738)

Subjects
Anticonvulsants -- Reports, Cannabinoids -- Reports, Epilepsy -- Reports, Stiripentol, Cannabidiol, Primidone, Levetiracetam, Phenols (Class of compounds), Rufinamide, Oxcarbazepine, Vigabatrin, Perampanel, Felbamate, Lacosamide, Lamotrigine, Zonisamide, Tiagabine, Editors, Business, Health
Abstract

2020 MAY 29 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Patent Business Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors [...]

Published
2020

24. Researchers Submit Patent Application, 'A19-144, A2-73 And Certain Anticholinesterase Inhibitor Compositions And Method For Anti-Seizure Therapy', for Approval (USPTO 20200038365)

Subjects
Glycoproteins, Memantine -- Intellectual property, Anticonvulsants -- Intellectual property, Seizures (Medicine), Stiripentol, Acetylcholine, Primidone, Levetiracetam, Rufinamide, Biotechnology, Ethotoin, Oxcarbazepine, Vigabatrin, Insurance industry, Perampanel, Felbamate, Phenacemide, Lacosamide, Lamotrigine, Zonisamide, Tiagabine, Editors, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2020 FEB 26 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- From Washington, D.C., NewsRx journalists report that a patent application by the inventors Missling, Christopher [...]

Published
2020

25. 'Transdermal Drug Delivery Devices And Methods' in Patent Application Approval Process (USPTO 20190336738)

Subjects
Nabilone -- Methods, Platelet aggregation inhibitors -- Intellectual property -- Methods, Lisdexamfetamine -- Methods, Suvorexant -- Intellectual property -- Methods, Amoxapine -- Intellectual property -- Methods, Lorcaserin -- Methods, Antimanic agents -- Intellectual property -- Methods, Febuxostat -- Methods, Droxidopa -- Methods, Memantine -- Intellectual property -- Methods, Anticonvulsants -- Intellectual property -- Methods, Antipsychotic agents -- Methods, Hypnotics and sedatives -- Intellectual property -- Methods, Antiparkinson agents -- Methods, Dolasetron -- Intellectual property -- Methods, Tasimelteon -- Methods, Pamidronate -- Intellectual property -- Methods, Dopamine agonists -- Methods, Bupivacaine -- Intellectual property -- Methods, Trimipramine -- Intellectual property -- Methods, Transdermal drug delivery systems -- Intellectual property -- Methods, Oxaprozin -- Intellectual property -- Methods, Tiotropium -- Intellectual property -- Methods, Acamprosate -- Intellectual property -- Methods, Antidepressants -- Intellectual property -- Methods, Armodafinil -- Methods, Zileuton -- Intellectual property -- Methods, Almotriptan -- Intellectual property -- Methods, Eletriptan -- Intellectual property -- Methods, Opioids -- Methods, Duloxetine, Loxapine, Sufentanil, Vortioxetine, Tapentadol, Rufinamide, Ezogabine, Brexpiprazole, Perampanel, Tirofiban, Clopidogrel, Tiagabine, Editors, Rasagiline, Levetiracetam, Remifentanil, Ramelteon, Oxcarbazepine, Ropinirole, Levomilnacipran, Lamotrigine, Entacapone, Drug delivery systems, Cabergoline, Biotechnology, Zaleplon, Vigabatrin, Eszopiclone, Tolcapone, Escitalopram, Lacosamide, Zonisamide, Alfentanil, Pramipexole, Vilazodone, Milnacipran, Fosphenytoin, Aripiprazole, Felbamate, Asenapine, Rotigotine, Prasugrel, Desvenlafaxine, Biotechnology industry, Biological sciences, Business
Abstract

2019 NOV 25 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- A patent application by the inventors JOHNSTON, Andrew L. (Redwood City, CA); SCHALLER, Michael [...]

Published
2019

27. Patent Application Titled 'Metabolic Restriction In Cell-Based Assays' Published Online (USPTO 20190234940)

Subjects
Anti-HIV agents, Asenapine, Cinacalcet -- Intellectual property, Vaccines -- Intellectual property, Midodrine -- Intellectual property, Fenofibrate -- Intellectual property, Felbamate, Clopidogrel -- Intellectual property, Febuxostat, Protease inhibitors -- Intellectual property, Escitalopram -- Intellectual property, Clemastine -- Intellectual property, Posaconazole, Oxcarbazepine, Halofantrine -- Intellectual property, Abiraterone -- Intellectual property, Metronidazole -- Intellectual property, Tegaserod -- Intellectual property, Thioridazine -- Intellectual property, Aprepitant -- Intellectual property, Ezetimibe, Enoxacin -- Intellectual property, Sulfinpyrazone -- Intellectual property, Duloxetine -- Intellectual property, Tripelennamine -- Intellectual property, Efavirenz, Tipranavir, Editors, Atazanavir, Delavirdine, Liver diseases, Boceprevir, Phenylbutazone, Telaprevir, Health
Abstract

2019 AUG 21 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Weekly -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2019

28. Patent Issued for Transdermal Administration Of Memantine (USPTO 10,363,228)

Subjects
Nervous system agents, Felbamate, Transdermal drug delivery systems -- Intellectual property, Memantine -- Intellectual property, Acamprosate -- Intellectual property, Alzheimer's disease, Mental health, Health, Editors, Health, Psychology and mental health
Abstract

2019 AUG 12 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- LTS Lohmann Therapie-Systeme AG has been issued patent number 10,363,228, according to news [...]

Published
2019

29. Patent Issued for Therapeutic Approaches For Treating CMT And Related Disorders (USPTO 10,322,101)

Subjects
Balsalazide -- Intellectual property, Fenofibrate -- Intellectual property, Felbamate, Methimazole -- Intellectual property, Phenoxybenzamine -- Intellectual property, Loxapine, Dutasteride -- Intellectual property, Flumazenil -- Intellectual property, Biotechnology, Editors, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2019 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the [...]

Published
2019

30. 'Formulation For Inhibiting Formation Of 5-Ht2b Agonists And Methods Of Using Same' in Patent Application Approval Process (USPTO 20190083425)

Subjects
Drug discovery -- Methods, Brivaracetam -- Methods, Epilepsy -- Methods, Anticonvulsants -- Intellectual property -- Methods, Ethotoin, Vigabatrin, Mephenytoin, Felbamate, Rufinamide, Primidone, Perampanel, Editors, Phenacemide, Lacosamide, Tiagabine, Oxcarbazepine, Zonisamide, Methsuximide, Pharmaceuticals and cosmetics industries
Abstract

2019 APR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A patent application by the inventors FARR, Stephen J. (Orinda, CA); BOYD, BROOKS (Berkeley, CA), [...]

Published
2019

31. Patent Application Titled 'Formulation For Inhibiting Formation Of 5-Ht2b Agonists And Methods Of Using Same' Published Online (USPTO 20190083424)

Subjects
Drug discovery -- Methods, Brivaracetam -- Methods, Epilepsy -- Methods, Anticonvulsants -- Intellectual property -- Methods, Ethotoin, Vigabatrin, Mephenytoin, Felbamate, Rufinamide, Primidone, Perampanel, Editors, Phenacemide, Lacosamide, Tiagabine, Oxcarbazepine, Zonisamide, Methsuximide, Health
Abstract

2019 APR 8 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by [...]

Published
2019

32. New Findings from University of Aquila in Epilepsy Provides New Insights (The pharmacological management of Lennox-Gastaut syndrome and critical literature review)

Subjects
Seizures (Medicine), Medical research, Epilepsy, Anticonvulsants, Zonisamide, Electroencephalography, Central nervous system, Lamotrigine, Felbamate, Rufinamide, Levetiracetam, Perampanel, Encephalopathy, Editors, Health
Abstract

2019 FEB 1 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Research findings on Central Nervous System Diseases and Conditions - Epilepsy are discussed [...]

Published
2019

33. Patent Issued for Substituted Diketopiperazine Analogs For Use As Drug Delivery Agents (USPTO 10,172,850)

Subjects
Mannkind Corp. -- Intellectual property, Lamotrigine, Vardenafil, Clopidogrel, Drug delivery systems, Felbamate, Biotechnology industries, Biotechnology, Editors, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2019 JAN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- MannKind Corporation (Valencia, California, United States) has been issued patent number 10,172,850, according to news [...]

Published
2019

34. Divalproex sodium delayed release, Depakote, Depakote Sprinkle capsules, Divalproex sodium extended release, Depakote ER, Depakene, Valproic acid (Brand: Valproate)

Subjects
Anticonvulsants, Valproic acid, Felbamate, Lamotrigine, Family and marriage, Health, Psychology and mental health
Abstract

What is valproate? Divalproex sodium, valproic acid, and valproate sodium belong to the group of medicines known as anticonvulsants, as they were originally developed to treat convulsions in patients with [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results